The battle against brain cancer is an ongoing quest, and a recent development in the field of medicine has emerged as a promising new weapon: Intratumoral Modulation Therapy (IMT). This innovative approach, developed by Dr. Matthew Hebb and a team of interdisciplinary researchers at Western University, utilizes low-amplitude electric fields to disrupt the growth of glioblastoma, one of the most aggressive and difficult-to-treat brain cancers. The team's latest study, published in Neuro-Oncology Advances, demonstrates the safety and effectiveness of IMT in delivering stronger, dynamic electric fields directly to glioblastoma tumours in animal models, significantly slowing tumour growth.
What makes IMT particularly fascinating is its unique approach to cancer treatment. Unlike traditional methods that use electricity to burn or destroy tumours, IMT employs chronic low-amplitude electric fields to interfere with cancer cell division. This subtle yet powerful technique prevents cancer cells from dividing properly, effectively stalling their growth. The research team, led by Hebb and including physicists, biomedical engineers, and medical professionals, has made significant progress in understanding the biological mechanisms behind IMT's success.
One of the key challenges in treating tumours inside the brain is precisely controlling the electric field's location and strength. Erin Iredale, a postdoctoral researcher and first author on the study, has played a pivotal role in addressing this issue. Her work in the Hebb lab has led to the development of a treatment-planning system that can help physicians personalize IMT for individual patients. This system uses computational modelling and an optimization algorithm to determine the optimal placement of electrodes and stimulation parameters, ensuring that the electric field effectively targets the tumour while minimizing potential side effects.
The latest study, conducted in rats, marks a significant milestone in the IMT project. It is the first time the team has used multiple electrodes in a living brain to create a dynamic electric field. By shifting the phase of electrical signals delivered by each electrode, the researchers were able to rotate the electric field over time, covering the tumour more completely and reducing the likelihood of 'cold spots' where cancer cells might escape treatment. The results were impressive, with an eight-fold reduction in tumour growth and a five-fold reduction in tumour volume after just seven days of treatment.
Iredale's passion for combining physics and mathematics with practical patient care has driven her dedication to the IMT project. She believes that the interdisciplinary nature of the research is crucial to solving complex healthcare challenges. As the team continues to refine the treatment-planning system and develop a prototype for clinical trials, Iredale remains optimistic about the future of IMT. She envisions a world where IMT becomes a standard treatment option for patients with brain cancer, offering a glimmer of hope in the fight against this devastating disease.
In my opinion, the development of IMT is a testament to the power of interdisciplinary collaboration in medical research. It highlights the importance of bringing together experts from diverse fields to tackle complex problems. As we continue to explore the potential of electric fields in cancer treatment, IMT serves as a reminder that innovation and perseverance can lead to groundbreaking discoveries that improve the lives of patients worldwide.
